Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 155

1.

Macular spatial distribution of preserved autofluorescence in patients with choroideremia.

Hariri AH, Ip MS, Girach A, Lam BL, Fischer MD, Sankila EM, Pennesi ME, Holz FG, Maclaren RE, Birch DG, Hoyng CB, MacDonald IM, Black GC, Tsang SH, Bressler NM, Stepien KE, Larsen M, Gorin MB, Meunier I, Webster AR, Sadda S.

Br J Ophthalmol. 2018 Oct 8. pii: bjophthalmol-2018-312620. doi: 10.1136/bjophthalmol-2018-312620. [Epub ahead of print]

PMID:
30297337
2.

Crystals and Fatty Acid Abnormalities Are Not Present in Circulating Cells From Choroideremia Patients.

Radziwon A, Cho WJ, Szkotak A, Suh M, MacDonald IM.

Invest Ophthalmol Vis Sci. 2018 Sep 4;59(11):4464-4470. doi: 10.1167/iovs.18-25112.

PMID:
30193321
3.

Two-Year Results After AAV2-Mediated Gene Therapy for Choroideremia: The Alberta Experience.

Dimopoulos IS, Hoang SC, Radziwon A, Binczyk NM, Seabra MC, MacLaren RE, Somani R, Tennant MTS, MacDonald IM.

Am J Ophthalmol. 2018 Sep;193:130-142. doi: 10.1016/j.ajo.2018.06.011. Epub 2018 Jun 27.

PMID:
29940166
4.

Investigation of the effect of dietary docosahexaenoic acid (DHA) supplementation on macular function in subjects with autosomal recessive Stargardt macular dystrophy.

MacDonald IM, Sieving PA.

Ophthalmic Genet. 2018 Aug;39(4):477-486. doi: 10.1080/13816810.2018.1484931. Epub 2018 Jun 18.

PMID:
29912604
5.

American Journal of Ophthalmology Contributions to Ophthalmic Genetics.

MacDonald IM, Sieving PC.

Am J Ophthalmol. 2018 Jun;190:xvi-xxi. doi: 10.1016/j.ajo.2018.03.004. Epub 2018 Mar 9.

PMID:
29530780
6.

THE NATURAL HISTORY OF FULL-FIELD STIMULUS THRESHOLD DECLINE IN CHOROIDEREMIA.

Dimopoulos IS, Freund PR, Knowles JA, MacDonald IM.

Retina. 2018 Sep;38(9):1731-1742. doi: 10.1097/IAE.0000000000001764.

PMID:
28800019
7.

Rituximab for the Treatment of Autoimmune Retinopathy.

Forooghian F, MacDonald IM.

Am J Ophthalmol. 2017 Aug;180:xv-xvi. doi: 10.1016/j.ajo.2017.06.006. Epub 2017 Jun 27. No abstract available.

PMID:
28662767
8.

Choroideremia.

Dimopoulos IS, Radziwon A, St Laurent CD, MacDonald IM.

Curr Opin Ophthalmol. 2017 Sep;28(5):410-415. doi: 10.1097/ICU.0000000000000392. Review.

PMID:
28520608
9.

Measurement and Reproducibility of Preserved Ellipsoid Zone Area and Preserved Retinal Pigment Epithelium Area in Eyes With Choroideremia.

Hariri AH, Velaga SB, Girach A, Ip MS, Le PV, Lam BL, Fischer MD, Sankila EM, Pennesi ME, Holz FG, MacLaren RE, Birch DG, Hoyng CB, MacDonald IM, Black GC, Tsang SH, Bressler NM, Larsen M, Gorin MB, Webster AR, Sadda SR; Natural History of the Progression of Choroideremia (NIGHT) Study Group.

Am J Ophthalmol. 2017 Jul;179:110-117. doi: 10.1016/j.ajo.2017.05.002. Epub 2017 May 10.

PMID:
28499705
10.

RETINAL PHENOTYPE IN A CASE OF LCHAD/TFP DEFICIENCY WITH LATE-STAGE DIAGNOSIS.

Knowles JA, Dimopoulos IS, MacDonald IM.

Retin Cases Brief Rep. 2017 Mar 15. doi: 10.1097/ICB.0000000000000579. [Epub ahead of print]

PMID:
28301411
11.

Single-base substitutions in the CHM promoter as a cause of choroideremia.

Radziwon A, Arno G, K Wheaton D, McDonagh EM, Baple EL, Webb-Jones K, G Birch D, Webster AR, MacDonald IM.

Hum Mutat. 2017 Jun;38(6):704-715. doi: 10.1002/humu.23212. Epub 2017 Mar 24.

PMID:
28271586
12.

Perspectives on Canadian Postgraduate Education in Ophthalmology.

MacDonald IM, Hurley B, Seamone C.

Can J Ophthalmol. 2016 Oct;51(5):311-313. doi: 10.1016/j.jcjo.2016.06.006. Epub 2016 Aug 27. No abstract available.

PMID:
27769318
13.

Resolving Genetic Test Results for the Patient and the Clinician.

Chan SC, MacDonald IM.

Am J Ophthalmol. 2016 Oct;170:xiv-xvi. doi: 10.1016/j.ajo.2016.08.014. Epub 2016 Sep 14. No abstract available.

PMID:
27639845
14.

Microperimetry as an Outcome Measure in Choroideremia Trials: Reproducibility and Beyond.

Dimopoulos IS, Tseng C, MacDonald IM.

Invest Ophthalmol Vis Sci. 2016 Aug 1;57(10):4151-61. doi: 10.1167/iovs.16-19338.

PMID:
27537265
15.

Brothers with ocular motor apraxia, juvenile nephronophthisis, and mild cerebellar defects.

Chan SC, Rayat J, Sauvé Y, MacDonald IM.

Can J Ophthalmol. 2016 Jun;51(3):e85-8. doi: 10.1016/j.jcjo.2016.01.003. Epub 2016 Apr 16. No abstract available.

PMID:
27316287
16.

Reduction of Arachidonate Is Associated With Increase in B-Cell Activation Marker in Infants: A Randomized Trial.

Miklavcic JJ, Larsen BM, Mazurak VC, Scalabrin DM, MacDonald IM, Shoemaker GK, Casey L, Van Aerde JE, Clandinin MT.

J Pediatr Gastroenterol Nutr. 2017 Mar;64(3):446-453. doi: 10.1097/MPG.0000000000001283.

PMID:
27276431
17.

Analysis of a large choroideremia dataset does not suggest a preference for inclusion of certain genotypes in future trials of gene therapy.

Freund PR, Sergeev YV, MacDonald IM.

Mol Genet Genomic Med. 2016 Feb 28;4(3):344-58. doi: 10.1002/mgg3.208. eCollection 2016 May.

18.

Oculomotor apraxia and dilated cardiomyopathy with ataxia syndrome: A case report.

Benson MD, Ferreira P, MacDonald IM.

Ophthalmic Genet. 2017 Jan-Feb;38(1):88-90. doi: 10.3109/13816810.2015.1137327. Epub 2016 Apr 7.

PMID:
27054461
19.

Choroideremia research: Report and perspectives on the second international scientific symposium for choroideremia.

Chan SC, Bubela T, Dimopoulos IS, Freund PR, Varkouhi AK, MacDonald IM.

Ophthalmic Genet. 2016 Sep;37(3):267-75. doi: 10.3109/13816810.2015.1088958. Epub 2016 Feb 8.

PMID:
26855058
20.

Pathogenic mechanisms and the prospect of gene therapy for choroideremia.

Dimopoulos IS, Chan S, MacLaren RE, MacDonald IM.

Expert Opin Orphan Drugs. 2015 Jul 1;3(7):787-798.

Supplemental Content

Loading ...
Support Center